Pharma CEO Hasnt Lowered Drug Price

“A 30-day, 30-pill supply of Daraprim would cost me $27,006 at my local pharmacy”, said Lydia Ramsey, from the Business Insider.

Shkreli, the creator and ceo of minion Turing Pharmaceuticals, was in fact vilified on social networking turned out to become the emblem for value gouging after his service provider grown the cost of a recently-purchased Remedies and cancerous tumors prescription, Daraprim, from usd13. Shkreli’s startup bought the drug, used to treat infections in AIDS patients and others with comproised immune systems, and hiked its price 5000% percent to $750 per dose.

In comparison, cycloserine, a tuberculosis drug that the New York Times highlighted early on in the drug outrage, announced its new lowered price within a day of the Times’ Sunday article that was tweeted by Democratic presidential candidate Hillary Clinton.

Following the hike announcement, Shkreli became the face of corporate greed. The same can not be said of Craig Rothenberg, Turing’s chief communication officer and a longtime Johnson & Johnson executive, who stepped down shortly after the controversy over Daraprim erupted.

“That boils down to about $900 a pill, which includes the wholesale cost, along with specific pharmacy fees based on the zip code I gave the pharmacy”.

“Yes, we have a plan”.

Drug boss Martin Shkreli, 32, also allegedly gained access to social media accounts belonging to that ex-employee, and contacted him and his relatives straight, like his teenage son and wife, as he accused the worker of defrauding Shkreli’s then-pharma firm, Retrophin. Shkreli says that’s one benefit of the price hike he instituted-it funds research and potential new treatments after decades of stagnation. “Every channel expert is paid for by our salary”, he applied.

WABE learned Shkreli was here in Atlanta last week to talk with the Centers for Disease Control and Prevention about the drug.

To listen to the interview between WABE’s Jim Burress and Turing Pharmaceutical’s CEO, Martin Shkreli, click the “listen” icon above. “I’m not sure it’s going to dramatically change the way I act”.